Press Release | 02.13.18

LOS ANGELES, CALIF., February 13, 2018 – Archer Norris is pleased to announce that patent client Immix Biopharma, Inc. has received Human Research Ethics Committee (IRB) approval to begin a Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in participants with advanced solid tumors. Imx-110 is a combination therapy designed to inhibit cancer resistance and evolvability. A privately-held biotechnology firm, Immix is co-founded by Archer Norris partner Sean D. Senn.

“Archer Norris is proud to see one of our startup clients achieve continued success with cutting-edge work in the biotechnology field,” said Managing Partner Doug Straus. “We are honored to work with Immix as they move into this next key phase of innovative research and studies.”

Serving as the Chair of Archer Norris’s patent practice, partner Sean Senn helps start and build effective companies with a strong focus on the biotech, pharma and medical device space. “Each milestone achieved by Immix throughout this process has implications not only for IMX-110 and cancer patients,” states Senn, “but is also important in laying the foundation for future life-saving innovations in the biotech field.”

About Archer Norris
A leading California law firm, Archer Norris PLC has 75+ attorneys admitted to practice in 12 states. The firm focuses on business law from four strategically located offices throughout California and wherever our clients need us.

For more information about the firm, please contact Melanie Conrad at 925.930.6600 or visit the Archer Norris website at

About Immix 
Immix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The team was founded by Vladimir Torchilin, PhD, D.Sc. Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; Ilya Rachman, an MD, PhD, MBA, physician scientist and clinical researcher; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney and fund manager. The company's goal is to harness scientific advances in order to engineer transformative, effective cancer treatments. For inquiries, contact Ryan Witt, Vice President, at

Name Title Phone Email V-card
Senn, Sean Partner 213.437.4000 vcard